Stock listing
A2RR34 Stock Price, News, Filings & Events — Arrowhead Pharmaceuticals, Inc.
Selected listing: A2RR34 · BMFBOVESPA · BRL · BR
This page tracks Arrowhead Pharmaceuticals, Inc.'s A2RR34:BMFBOVESPA listing on BMFBOVESPA in BRL for BR, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A2RR34:BMFBOVESPA. A2RR34:BMFBOVESPA is the stock-level entry point for investors researching Arrowhead Pharmaceuticals, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.

- Ticker
- A2RR34:BMFBOVESPA
- Asset type
- Stock
- Market cap
- $9.39B
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- BMFBOVESPA
- Currency
- BRL
Arrowhead Pharmaceuticals, Inc. A2RR34:BMFBOVESPA stock context
This page tracks Arrowhead Pharmaceuticals, Inc.'s A2RR34:BMFBOVESPA listing on BMFBOVESPA in BRL for BR, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A2RR34:BMFBOVESPA. A2RR34:BMFBOVESPA is the stock-level entry point for investors researching Arrowhead Pharmaceuticals, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
Latest news from Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
September 15, 2026
Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences
September 3, 2026
Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia
August 30, 2026
Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress
August 24, 2026
People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides
August 17, 2026
Arrowhead Pharmaceuticals, Inc. earnings calls
Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2026 Earnings Call
August 4, 2026 · Replay with transcript and chapters
Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2026 Earnings Call
May 7, 2026 · Replay with transcript and chapters
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2026 Earnings Call
February 5, 2026 · Replay with transcript and chapters
Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2025 Earnings Call
November 25, 2025 · Replay with transcript and chapters
Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2025 Earnings Call
August 7, 2025 · Replay with transcript and chapters
Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2025 Earnings Call
May 12, 2025 · Replay with transcript and chapters
Research Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. investor report
Review AI stock analysis and investor report context for A2RR34:BMFBOVESPA.
Arrowhead Pharmaceuticals, Inc. company profile
View the public company page for Arrowhead Pharmaceuticals, Inc. on 6ix.
Arrowhead Pharmaceuticals, Inc. news
Read company news and market updates connected to Arrowhead Pharmaceuticals, Inc..
Arrowhead Pharmaceuticals, Inc. investor events
Find investor webinars, events, and replay context for Arrowhead Pharmaceuticals, Inc..
Alternate listings
ARWR:NASDAQ
US · USD
Alternate listing for Arrowhead Pharmaceuticals, Inc.; the primary context on this page is A2RR34:BMFBOVESPA.
HDP1:GETTEX
DE · EUR
Alternate listing for Arrowhead Pharmaceuticals, Inc.; the primary context on this page is A2RR34:BMFBOVESPA.
A2AGYB:LSX
DE · EUR
Alternate listing for Arrowhead Pharmaceuticals, Inc.; the primary context on this page is A2RR34:BMFBOVESPA.
A2AGYB:LS
DE · EUR
Alternate listing for Arrowhead Pharmaceuticals, Inc.; the primary context on this page is A2RR34:BMFBOVESPA.
ARWR:BMV
MX · MXN
Alternate listing for Arrowhead Pharmaceuticals, Inc.; the primary context on this page is A2RR34:BMFBOVESPA.
0HI3:LSE
GB · USD
Alternate listing for Arrowhead Pharmaceuticals, Inc.; the primary context on this page is A2RR34:BMFBOVESPA.
ARWR:BOATS
US · USD
Alternate listing for Arrowhead Pharmaceuticals, Inc.; the primary context on this page is A2RR34:BMFBOVESPA.
HDP1:TRADEGATE
DE · EUR
Alternate listing for Arrowhead Pharmaceuticals, Inc.; the primary context on this page is A2RR34:BMFBOVESPA.
HDP1:FWB
DE · EUR
Alternate listing for Arrowhead Pharmaceuticals, Inc.; the primary context on this page is A2RR34:BMFBOVESPA.
HDP1:SWB
DE · EUR
Alternate listing for Arrowhead Pharmaceuticals, Inc.; the primary context on this page is A2RR34:BMFBOVESPA.
ARWR:BIVA
MX · MXN
Alternate listing for Arrowhead Pharmaceuticals, Inc.; the primary context on this page is A2RR34:BMFBOVESPA.
HDP1:BX
CH · CHF
Alternate listing for Arrowhead Pharmaceuticals, Inc.; the primary context on this page is A2RR34:BMFBOVESPA.